CA3177749A1 - Compositions comprising a cas12i2 variant polypeptide and uses thereof - Google Patents
Compositions comprising a cas12i2 variant polypeptide and uses thereofInfo
- Publication number
- CA3177749A1 CA3177749A1 CA3177749A CA3177749A CA3177749A1 CA 3177749 A1 CA3177749 A1 CA 3177749A1 CA 3177749 A CA3177749 A CA 3177749A CA 3177749 A CA3177749 A CA 3177749A CA 3177749 A1 CA3177749 A1 CA 3177749A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- variant
- cas12i2
- polypeptide
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (37)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063003090P | 2020-03-31 | 2020-03-31 | |
| US202063002999P | 2020-03-31 | 2020-03-31 | |
| US202063003064P | 2020-03-31 | 2020-03-31 | |
| US63/003,064 | 2020-03-31 | ||
| US63/003,090 | 2020-03-31 | ||
| US63/002,999 | 2020-03-31 | ||
| US202063012007P | 2020-04-17 | 2020-04-17 | |
| US63/012,007 | 2020-04-17 | ||
| US202063026562P | 2020-05-18 | 2020-05-18 | |
| US202063026277P | 2020-05-18 | 2020-05-18 | |
| US202063026523P | 2020-05-18 | 2020-05-18 | |
| US202063026606P | 2020-05-18 | 2020-05-18 | |
| US63/026,523 | 2020-05-18 | ||
| US63/026,606 | 2020-05-18 | ||
| US63/026,277 | 2020-05-18 | ||
| US63/026,562 | 2020-05-18 | ||
| US202063063819P | 2020-08-10 | 2020-08-10 | |
| US202063063859P | 2020-08-10 | 2020-08-10 | |
| US202063063831P | 2020-08-10 | 2020-08-10 | |
| US202063063879P | 2020-08-10 | 2020-08-10 | |
| US63/063,819 | 2020-08-10 | ||
| US63/063,879 | 2020-08-10 | ||
| US63/063,831 | 2020-08-10 | ||
| US63/063,859 | 2020-08-10 | ||
| US202063085752P | 2020-09-30 | 2020-09-30 | |
| US202063085792P | 2020-09-30 | 2020-09-30 | |
| US202063085895P | 2020-09-30 | 2020-09-30 | |
| US202063085862P | 2020-09-30 | 2020-09-30 | |
| US63/085,792 | 2020-09-30 | ||
| US63/085,895 | 2020-09-30 | ||
| US63/085,752 | 2020-09-30 | ||
| US63/085,862 | 2020-09-30 | ||
| US202163147850P | 2021-02-10 | 2021-02-10 | |
| US202163147968P | 2021-02-10 | 2021-02-10 | |
| US63/147,968 | 2021-02-10 | ||
| US63/147,850 | 2021-02-10 | ||
| PCT/US2021/025257 WO2021202800A1 (en) | 2020-03-31 | 2021-03-31 | Compositions comprising a cas12i2 variant polypeptide and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3177749A1 true CA3177749A1 (en) | 2021-10-07 |
Family
ID=75640000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3177749A Pending CA3177749A1 (en) | 2020-03-31 | 2021-03-31 | Compositions comprising a cas12i2 variant polypeptide and uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230332119A1 (enExample) |
| EP (1) | EP4127154A1 (enExample) |
| JP (1) | JP2023520504A (enExample) |
| KR (1) | KR20230009379A (enExample) |
| CN (2) | CN121380024A (enExample) |
| AU (1) | AU2021249119A1 (enExample) |
| BR (1) | BR112022019713A2 (enExample) |
| CA (1) | CA3177749A1 (enExample) |
| CO (1) | CO2022015170A2 (enExample) |
| IL (1) | IL296791A (enExample) |
| MX (1) | MX2022012189A (enExample) |
| WO (1) | WO2021202800A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015330699B2 (en) | 2014-10-10 | 2021-12-02 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| US20230193243A1 (en) * | 2020-05-29 | 2023-06-22 | Arbor Biotechnologies, Inc. | Compositions comprising a cas12i2 polypeptide and uses thereof |
| EP4237557A1 (en) * | 2020-10-30 | 2023-09-06 | Arbor Biotechnologies, Inc. | Compositions comprising an rna guide targeting pdcd1 and uses thereof |
| EP4347818A2 (en) * | 2021-06-01 | 2024-04-10 | Arbor Biotechnologies, Inc. | Gene editing systems comprising a crispr nuclease and uses thereof |
| IL308803A (en) | 2021-06-04 | 2024-01-01 | Arbor Biotechnologies Inc | Gene editing systems comprising guide RNA targeting hydroxy acid oxidase 1 (HAO1) and uses thereof |
| US20230034581A1 (en) * | 2021-06-04 | 2023-02-02 | Arbor Biotechnologies, Inc. | Gene editing systems comprising an rna guide targeting lactate dehydrogenase a (ldha) and uses thereof |
| WO2022256619A2 (en) | 2021-06-04 | 2022-12-08 | Arbor Biotechnologies, Inc. | Gene editing systems comprising an rna guide targeting transthyretin (ttr) and uses thereof |
| WO2023018856A1 (en) | 2021-08-11 | 2023-02-16 | Arbor Biotechnologies, Inc. | Gene editing systems comprising an rna guide targeting polypyrimidine tract binding protein 1 (ptbp1) and uses thereof |
| US20230203539A1 (en) | 2021-08-11 | 2023-06-29 | Arbor Biotechnologies, Inc. | Gene editing systems comprising an rna guide targeting stathmin 2 (stmn2) and uses thereof |
| WO2023034475A1 (en) | 2021-09-01 | 2023-03-09 | Arbor Biotechnologies, Inc. | Cells modified by a cas12i polypeptide |
| EP4399293A4 (en) * | 2021-09-10 | 2025-10-15 | Arbor Biotechnologies Inc | COMPOSITIONS COMPRISING A CAS12I POLYPEPTIDE AND USES THEREOF |
| CA3237337A1 (en) * | 2021-11-02 | 2023-05-11 | Huidagene Therapeutics (Singapore) Pte. Ltd. | Novel crispr-cas12i systems and uses thereof |
| TW202334421A (zh) * | 2021-11-05 | 2023-09-01 | 美商阿伯生物技術公司 | 包含靶向ciita之rna引導之組合物及其用途 |
| WO2023122433A1 (en) | 2021-12-22 | 2023-06-29 | Arbor Biotechnologies, Inc. | Gene editing systems targeting hydroxyacid oxidase 1 (hao1) and lactate dehydrogenase a (ldha) |
| CN118749029A (zh) * | 2022-01-24 | 2024-10-08 | 辉大(上海)生物科技有限公司 | 新型CRISPR-Cas12i系统及其用途 |
| CN118995668A (zh) * | 2022-04-25 | 2024-11-22 | 辉大基因治疗(新加坡)私人有限公司 | 新型CRISPR-Cas12i系统及其用途 |
| EP4627083A1 (en) | 2022-11-30 | 2025-10-08 | Arbor Biotechnologies, Inc. | Reverse transcriptase-mediated genetic editing of transthyretin (ttr) and uses thereof |
| KR20250151430A (ko) | 2023-02-15 | 2025-10-21 | 아버 바이오테크놀로지스, 인크. | 스타스민 2(stmn2) 전사체에서 비정상적인 스플라이싱을 억제하는 유전자 편집 방법 |
| WO2025096594A2 (en) | 2023-10-30 | 2025-05-08 | Allogene Therapeutics, Inc. | Cells expressing anti-cd19 chimeric antigen receptors and methods of use thereof |
| CN117431235A (zh) * | 2023-11-06 | 2024-01-23 | 微光基因(苏州)有限公司 | CRISPR-Cas系统及其应用 |
| WO2025147604A1 (en) | 2024-01-05 | 2025-07-10 | Arbor Biotechnologies, Inc. | Methods for treating primary hyperoxaluria via genetic editing of hydroxyacid oxidase 1 |
| WO2025171210A1 (en) | 2024-02-09 | 2025-08-14 | Arbor Biotechnologies, Inc. | Compositions and methods for gene editing via homology-mediated end joining |
| WO2026015829A2 (en) | 2024-07-12 | 2026-01-15 | Arbor Biotechnologies, Inc. | Small reverse transcriptases and gene editing systems comprising such |
| WO2026015832A2 (en) | 2024-07-12 | 2026-01-15 | Arbor Biotechnologies, Inc. | Reverse transcriptases and gene editing systems comprising such |
| CN120424908B (zh) * | 2025-07-10 | 2025-09-12 | 南京农业大学 | 一种基于LAMP与CRISPR/Cas的检测方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3031921B1 (en) | 2012-12-12 | 2025-03-12 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
| CN105492611A (zh) * | 2013-06-17 | 2016-04-13 | 布罗德研究所有限公司 | 用于序列操纵的优化的crispr-cas双切口酶系统、方法以及组合物 |
| CN106459995B (zh) | 2013-11-07 | 2020-02-21 | 爱迪塔斯医药有限公司 | 使用统治型gRNA的CRISPR相关方法和组合物 |
| WO2019178427A1 (en) * | 2018-03-14 | 2019-09-19 | Arbor Biotechnologies, Inc. | Novel crispr dna targeting enzymes and systems |
| JP7693552B2 (ja) * | 2019-02-13 | 2025-06-17 | ビーム セラピューティクス インク． | アデノシンデアミナーゼ塩基エディターおよびそれを用いて標的配列中の核酸塩基を改変する方法 |
| WO2024178144A1 (en) * | 2023-02-22 | 2024-08-29 | Prime Medicine, Inc. | Methods and compositions for editing nucleotide sequences |
-
2021
- 2021-03-31 CN CN202511379190.7A patent/CN121380024A/zh active Pending
- 2021-03-31 CA CA3177749A patent/CA3177749A1/en active Pending
- 2021-03-31 KR KR1020227037945A patent/KR20230009379A/ko active Pending
- 2021-03-31 BR BR112022019713A patent/BR112022019713A2/pt unknown
- 2021-03-31 EP EP21720912.1A patent/EP4127154A1/en active Pending
- 2021-03-31 MX MX2022012189A patent/MX2022012189A/es unknown
- 2021-03-31 WO PCT/US2021/025257 patent/WO2021202800A1/en not_active Ceased
- 2021-03-31 US US17/916,270 patent/US20230332119A1/en active Pending
- 2021-03-31 JP JP2022560154A patent/JP2023520504A/ja active Pending
- 2021-03-31 CN CN202180038904.1A patent/CN115698278B/zh active Active
- 2021-03-31 AU AU2021249119A patent/AU2021249119A1/en active Pending
- 2021-03-31 IL IL296791A patent/IL296791A/en unknown
-
2022
- 2022-10-25 CO CONC2022/0015170A patent/CO2022015170A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021202800A1 (en) | 2021-10-07 |
| CN121380024A (zh) | 2026-01-23 |
| CO2022015170A2 (es) | 2022-11-08 |
| IL296791A (en) | 2022-11-01 |
| JP2023520504A (ja) | 2023-05-17 |
| BR112022019713A2 (pt) | 2022-12-20 |
| MX2022012189A (es) | 2023-01-05 |
| CN115698278A (zh) | 2023-02-03 |
| KR20230009379A (ko) | 2023-01-17 |
| EP4127154A1 (en) | 2023-02-08 |
| CN115698278B (zh) | 2025-10-17 |
| US20230332119A1 (en) | 2023-10-19 |
| AU2021249119A1 (en) | 2022-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115698278B (zh) | 包含Cas12i2变体多肽的组合物及其用途 | |
| US20240174997A1 (en) | Compositions comprising a variant polypeptide and uses thereof | |
| US20240035010A1 (en) | Compositions comprising a variant polypeptide and uses thereof | |
| US20250290053A1 (en) | Compositions comprising a crispr nuclease and uses thereof | |
| US11946045B2 (en) | Compositions comprising a variant polypeptide and uses thereof | |
| US11866746B2 (en) | Compositions comprising a variant Cas12i4 polypeptide and uses thereof | |
| US20240352434A1 (en) | Compositions comprising a variant cas12i3 polypeptide and uses thereof | |
| WO2024020557A1 (en) | Compositions comprising a variant nuclease and uses thereof | |
| WO2022150608A1 (en) | Compositions comprising a variant crispr nuclease polypeptide and uses thereof | |
| CN117136233A (zh) | 包含变体Cas12i4多肽的组合物及其用途 | |
| CN117043326A (zh) | 包含变体多肽的组合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220928 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250226 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250819 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250912 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260109 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260126 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260126 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260126 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260219 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260219 |